{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T06:39:31Z","timestamp":1784702371431,"version":"3.55.0"},"reference-count":67,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2014,8,20]],"date-time":"2014-08-20T00:00:00Z","timestamp":1408492800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Psychiatry Rep"],"published-print":{"date-parts":[[2014,10]]},"DOI":"10.1007\/s11920-014-0473-9","type":"journal-article","created":{"date-parts":[[2014,8,19]],"date-time":"2014-08-19T06:33:40Z","timestamp":1408430020000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":72,"title":["Antipsychotic Induced Weight Gain: Genetics, Epigenetics, and Biomarkers Reviewed"],"prefix":"10.1007","volume":"16","author":[{"given":"Tahireh A.","family":"Shams","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel J.","family":"M\u00fcller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,8,20]]},"reference":[{"issue":"1","key":"473_CR1","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1002\/j.2051-5545.2008.tb00154.x","volume":"7","author":"A Ucok","year":"2008","unstructured":"Ucok A, Gaebel W. Side effects of atypical antipsychotics: a brief overview. World Psychiatry. 2008;7(1):58\u201362.","journal-title":"World Psychiatry"},{"issue":"2","key":"473_CR2","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1111\/j.1365-2710.2009.01084.x","volume":"35","author":"S Gebhardt","year":"2010","unstructured":"Gebhardt S et al. Body weight gain induced by atypical antipsychotics: an extension of the monozygotic twin and sib pair study. J Clin Pharm Ther. 2010;35(2):207\u201311.","journal-title":"J Clin Pharm Ther"},{"issue":"5","key":"473_CR3","doi-asserted-by":"crossref","first-page":"509","DOI":"10.3109\/09540261.2013.825579","volume":"25","author":"CA Altar","year":"2013","unstructured":"Altar CA et al. Clinical validity of cytochrome P450 metabolism and serotonin gene variants in psychiatric pharmacotherapy. Int Rev Psychiatry. 2013;25(5):509\u201333.","journal-title":"Int Rev Psychiatry"},{"issue":"3","key":"473_CR4","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1038\/mp.2011.109","volume":"17","author":"TA Lett","year":"2012","unstructured":"Lett TA et al. Pharmacogenetics of antipsychotic-induced weight gain: review and clinical implications. Mol Psychiatry. 2012;17(3):242\u201366.","journal-title":"Mol Psychiatry"},{"issue":"16","key":"473_CR5","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.2217\/pgs.13.207","volume":"14","author":"AC Kao","year":"2013","unstructured":"Kao AC, M\u00fcller DJ. Genetics of antipsychotic-induced weight gain: update and current perspectives. Pharmacogenomics. 2013;14(16):2067\u201383. Comprehensive, detailed, and most recent review on AIWG.","journal-title":"Pharmacogenomics"},{"issue":"2","key":"473_CR6","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1097\/YCO.0b013e32835dc9da","volume":"26","author":"DJ M\u00fcller","year":"2013","unstructured":"M\u00fcller DJ, Chowdhury NI, Zai CC. The pharmacogenetics of antipsychotic-induced adverse events. Curr Opin Psychiatry. 2013;26(2):144\u201350.","journal-title":"Curr Opin Psychiatry"},{"issue":"4","key":"473_CR7","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.phrs.2003.05.001","volume":"49","author":"DJ M\u00fcller","year":"2004","unstructured":"M\u00fcller DJ et al. Pharmacogenetics of antipsychotic-induced weight gain. Pharmacol Res. 2004;49(4):309\u201329.","journal-title":"Pharmacol Res"},{"issue":"6","key":"473_CR8","doi-asserted-by":"crossref","first-page":"863","DOI":"10.2217\/14622416.7.6.863","volume":"7","author":"DJ M\u00fcller","year":"2006","unstructured":"M\u00fcller DJ, Kennedy JL. Genetics of antipsychotic treatment emergent weight gain in schizophrenia. Pharmacogenomics. 2006;7(6):863\u201387.","journal-title":"Pharmacogenomics"},{"issue":"9","key":"473_CR9","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1001\/archgenpsychiatry.2012.191","volume":"69","author":"AK Malhotra","year":"2012","unstructured":"Malhotra AK et al. Association between common variants near the melanocortin 4 receptor gene and severe antipsychotic drug-induced weight gain. Arch Gen Psychiatry. 2012;69(9):904\u201312.","journal-title":"Arch Gen Psychiatry"},{"issue":"3","key":"473_CR10","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1038\/tpj.2011.66","volume":"13","author":"NI Chowdhury","year":"2013","unstructured":"Chowdhury NI et al. Genetic association study between antipsychotic-induced weight gain and the melanocortin-4 receptor gene. Pharmacogenomics J. 2013;13(3):272\u20139.","journal-title":"Pharmacogenomics J"},{"key":"473_CR11","doi-asserted-by":"crossref","first-page":"e274","DOI":"10.1038\/tp.2013.26","volume":"3","author":"EL Nurmi","year":"2013","unstructured":"Nurmi EL et al. Moderation of antipsychotic-induced weight gain by energy balance gene variants in the RUPP autism network risperidone studies. Transl Psychiatry. 2013;3:e274.","journal-title":"Transl Psychiatry"},{"issue":"4","key":"473_CR12","doi-asserted-by":"crossref","first-page":"477","DOI":"10.2217\/pgs.13.220","volume":"15","author":"SN Roffeei","year":"2014","unstructured":"Roffeei SN et al. Association of FTO, LEPR and MTHFR gene polymorphisms with metabolic syndrome in schizophrenia patients receiving antipsychotics. Pharmacogenomics. 2014;15(4):477\u201385.","journal-title":"Pharmacogenomics"},{"issue":"1","key":"473_CR13","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1097\/JCP.0b013e31827772db","volume":"33","author":"F Czerwensky","year":"2013","unstructured":"Czerwensky F, Leucht S, Steimer W. Association of the common MC4R rs17782313 polymorphism with antipsychotic-related weight gain. J Clin Psychopharmacol. 2013;33(1):74\u20139.","journal-title":"J Clin Psychopharmacol"},{"issue":"9","key":"473_CR14","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1017\/S1461145713000849","volume":"16","author":"F Czerwensky","year":"2013","unstructured":"Czerwensky F, Leucht S, Steimer W. MC4R rs489693: a clinical risk factor for second generation antipsychotic-related weight gain? Int J Neuropsychopharmacol. 2013;16(9):2103\u20139. Independent replication of the rs489693 marker of MC4R in AIWG.","journal-title":"Int J Neuropsychopharmacol"},{"issue":"2","key":"473_CR15","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.pnpbp.2012.03.001","volume":"38","author":"EJ Brandl","year":"2012","unstructured":"Brandl EJ et al. Association study of polymorphisms in leptin and leptin receptor genes with antipsychotic-induced body weight gain. Prog Neuropsychopharmacol Biol Psychiatry. 2012;38(2):134\u201341.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"issue":"3","key":"473_CR16","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1017\/S1461145713001375","volume":"17","author":"U Srisawat","year":"2014","unstructured":"Srisawat U et al. Methylenetetrahydrofolate reductase (MTHFR) 677C\/T polymorphism is associated with antipsychotic-induced weight gain in first-episode schizophrenia. Int J Neuropsychopharmacol. 2014;17(3):485\u201390.","journal-title":"Int J Neuropsychopharmacol"},{"issue":"16","key":"473_CR17","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1001\/jama.288.16.2023","volume":"288","author":"M Klerk","year":"2002","unstructured":"Klerk M et al. MTHFR 677C\u2013 > T polymorphism and risk of coronary heart disease: a meta-analysis. JAMA. 2002;288(16):2023\u201331.","journal-title":"JAMA"},{"key":"473_CR18","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1146\/annurev.med.49.1.31","volume":"49","author":"H Refsum","year":"1998","unstructured":"Refsum H et al. Homocysteine and cardiovascular disease. Annu Rev Med. 1998;49:31\u201362.","journal-title":"Annu Rev Med"},{"issue":"7","key":"473_CR19","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.jpsychires.2009.10.011","volume":"44","author":"R Garcia-Miss Mdel","year":"2010","unstructured":"Garcia-Miss Mdel R et al. Folate, homocysteine, interleukin-6, and tumor necrosis factor alfa levels, but not the methylenetetrahydrofolate reductase C677T polymorphism, are risk factors for schizophrenia. J Psychiatr Res. 2010;44(7):441\u20136.","journal-title":"J Psychiatr Res"},{"issue":"3","key":"473_CR20","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.biopsych.2005.10.009","volume":"60","author":"J Levine","year":"2006","unstructured":"Levine J et al. Homocysteine-reducing strategies improve symptoms in chronic schizophrenic patients with hyperhomocysteinemia. Biol Psychiatry. 2006;60(3):265\u20139.","journal-title":"Biol Psychiatry"},{"issue":"2","key":"473_CR21","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/sj.mp.4001746","volume":"11","author":"JW Muntjewerff","year":"2006","unstructured":"Muntjewerff JW et al. Homocysteine, methylenetetrahydrofolate reductase and risk of schizophrenia: a meta-analysis. Mol Psychiatry. 2006;11(2):143\u20139.","journal-title":"Mol Psychiatry"},{"issue":"1","key":"473_CR22","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1002\/hup.2366","volume":"29","author":"SN Roffeei","year":"2014","unstructured":"Roffeei SN et al. Association of ADRA2A and MTHFR gene polymorphisms with weight loss following antipsychotic switching to aripiprazole or ziprasidone. Hum Psychopharmacol. 2014;29(1):38\u201345.","journal-title":"Hum Psychopharmacol"},{"key":"473_CR23","doi-asserted-by":"crossref","unstructured":"Kao, A.C., et al., Methylenetetrahydrofolate reductase gene variants and antipsychotic-induced weight gain and metabolic disturbances. J Psychiatr Res, 2014.","DOI":"10.1016\/j.jpsychires.2014.03.012"},{"issue":"3","key":"473_CR24","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.euroneuro.2012.05.008","volume":"23","author":"B Nowrouzi","year":"2013","unstructured":"Nowrouzi B et al. Finite mixture regression model analysis on antipsychotics induced weight gain: investigation of the role of the serotonergic genes. Eur Neuropsychopharmacol. 2013;23(3):224\u20138.","journal-title":"Eur Neuropsychopharmacol"},{"key":"473_CR25","unstructured":"del Castillo N, B.Z.M., Tyler B, Ellingrod VL, Calarge C, 759C\/T Variants of the Serotonin (5-HT2C) Receptor Gene and Weight Gain in Children and Adolescents in Long-Term Risperidone Treatment. Clinic Pharmacol Biopharmaceut 2013. 2(110)."},{"issue":"11","key":"473_CR26","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.2217\/pgs.10.123","volume":"11","author":"MN Sicard","year":"2010","unstructured":"Sicard MN et al. Polymorphisms of the HTR2C gene and antipsychotic-induced weight gain: an update and meta-analysis. Pharmacogenomics. 2010;11(11):1561\u201371.","journal-title":"Pharmacogenomics"},{"key":"473_CR27","first-page":"83","volume":"4","author":"TJ Wallace","year":"2011","unstructured":"Wallace TJ et al. Role of 5-HT(2C) receptor gene variants in antipsychotic-induced weight gain. Pharmgenomics Pers Med. 2011;4:83\u201393.","journal-title":"Pharmgenomics Pers Med"},{"key":"473_CR28","unstructured":"SLC6A4 solute carrier family 6 (neurotransmitter transporter), member 4 [ Homo sapiens (human) ]. April 8 2014 [cited 2014 April 9]; Available from: http:\/\/www.ncbi.nlm.nih.gov.ezproxy.lib.ryerson.ca\/gene\/6532 ."},{"issue":"2","key":"473_CR29","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1038\/tpj.2011.57","volume":"13","author":"B Almoguera","year":"2013","unstructured":"Almoguera B et al. Association of common genetic variants with risperidone adverse events in a Spanish schizophrenic population. Pharmacogenomics J. 2013;13(2):197\u2013204.","journal-title":"Pharmacogenomics J"},{"issue":"8","key":"473_CR30","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1016\/j.metabol.2009.11.007","volume":"59","author":"J Bah","year":"2010","unstructured":"Bah J et al. Further exploration of the possible influence of polymorphisms in HTR2C and 5HTT on body weight. Metabolism. 2010;59(8):1156\u201363.","journal-title":"Metabolism"},{"key":"473_CR31","unstructured":"HRH1 histamine receptor H1 [ Homo sapiens (human) ]. April 8 2014 [cited 2014 April 9]; Available from: http:\/\/www.ncbi.nlm.nih.gov.ezproxy.lib.ryerson.ca\/gene\/?term=h1hr ."},{"issue":"6","key":"473_CR32","doi-asserted-by":"crossref","first-page":"358","DOI":"10.4088\/JCP.v60n0602","volume":"60","author":"DA Wirshing","year":"1999","unstructured":"Wirshing DA et al. Novel antipsychotics: comparison of weight gain liabilities. J Clin Psychiatry. 1999;60(6):358\u201363.","journal-title":"J Clin Psychiatry"},{"issue":"3","key":"473_CR33","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1097\/JCP.0b013e3182900c9e","volume":"33","author":"BR Godlewska","year":"2013","unstructured":"Godlewska BR et al. Polymorphisms of the histamine receptor (H1HR) gene are not associated with olanzapine-induced weight gain. J Clin Psychopharmacol. 2013;33(3):436\u20137.","journal-title":"J Clin Psychopharmacol"},{"issue":"12","key":"473_CR34","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1038\/nchembio.687","volume":"7","author":"G Jia","year":"2011","unstructured":"Jia G et al. N6-methyladenosine in nuclear RNA is a major substrate of the obesity-associated FTO. Nat Chem Biol. 2011;7(12):885\u20137.","journal-title":"Nat Chem Biol"},{"issue":"5826","key":"473_CR35","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1126\/science.1141634","volume":"316","author":"TM Frayling","year":"2007","unstructured":"Frayling TM et al. A common variant in the FTO gene is associated with body mass index and predisposes to childhood and adult obesity. Science. 2007;316(5826):889\u201394.","journal-title":"Science"},{"issue":"6","key":"473_CR36","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1017\/S1461145712001435","volume":"16","author":"GP Reynolds","year":"2013","unstructured":"Reynolds GP et al. The obesity risk gene FTO influences body mass in chronic schizophrenia but not initial antipsychotic drug-induced weight gain in first-episode patients. Int J Neuropsychopharmacol. 2013;16(6):1421\u20135.","journal-title":"Int J Neuropsychopharmacol"},{"issue":"1","key":"473_CR37","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1159\/000356231","volume":"69","author":"EC Shing","year":"2014","unstructured":"Shing EC et al. Fat mass- and obesity-associated (FTO) gene and antipsychotic-induced weight gain: an association study. Neuropsychobiology. 2014;69(1):59\u201363.","journal-title":"Neuropsychobiology"},{"key":"473_CR38","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.pnpbp.2012.12.007","volume":"43","author":"X Hu","year":"2013","unstructured":"Hu X et al. Association study of NRXN3 polymorphisms with schizophrenia and risperidone-induced bodyweight gain in Chinese Han population. Prog Neuropsychopharmacol Biol Psychiatry. 2013;43:197\u2013202.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"473_CR39","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1146\/annurev-biochem-060109-094246","volume":"81","author":"JS Bogan","year":"2012","unstructured":"Bogan JS. Regulation of glucose transporter translocation in health and diabetes. Annu Rev Biochem. 2012;81:507\u201332.","journal-title":"Annu Rev Biochem"},{"issue":"2","key":"473_CR40","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1002\/hup.2288","volume":"28","author":"EJ Brandl","year":"2013","unstructured":"Brandl EJ et al. Exploratory study on association of genetic variation in TBC1D1 with antipsychotic-induced weight gain. Hum Psychopharmacol. 2013;28(2):183\u20137. One of the first studies implicating genes from glucose metabolism, particularly TBC1D1.","journal-title":"Hum Psychopharmacol"},{"issue":"6","key":"473_CR41","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1038\/npp.2009.235","volume":"35","author":"AK Tiwari","year":"2010","unstructured":"Tiwari AK et al. A common polymorphism in the cannabinoid receptor 1 (CNR1) gene is associated with antipsychotic-induced weight gain in Schizophrenia. Neuropsychopharmacology. 2010;35(6):1315\u201324.","journal-title":"Neuropsychopharmacology"},{"issue":"1","key":"473_CR42","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1097\/JCP.0b013e31827d145a","volume":"33","author":"AK Tiwari","year":"2013","unstructured":"Tiwari AK et al. Association of a functional polymorphism in neuropeptide Y with antipsychotic-induced weight gain in schizophrenia patients. J Clin Psychopharmacol. 2013;33(1):11\u20137.","journal-title":"J Clin Psychopharmacol"},{"issue":"5","key":"473_CR43","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.neuropharm.2005.04.017","volume":"49","author":"KM Gamber","year":"2005","unstructured":"Gamber KM, Macarthur H, Westfall TC. Cannabinoids augment the release of neuropeptide Y in the rat hypothalamus. Neuropharmacology. 2005;49(5):646\u201352.","journal-title":"Neuropharmacology"},{"issue":"3","key":"473_CR44","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1172\/JCI17725","volume":"112","author":"D Cota","year":"2003","unstructured":"Cota D et al. The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis. J Clin Invest. 2003;112(3):423\u201331.","journal-title":"J Clin Invest"},{"issue":"5","key":"473_CR45","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1172\/JCI200523057","volume":"115","author":"D Osei-Hyiaman","year":"2005","unstructured":"Osei-Hyiaman D et al. Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity. J Clin Invest. 2005;115(5):1298\u2013305.","journal-title":"J Clin Invest"},{"key":"473_CR46","unstructured":"NDUFS1 NADH dehydrogenase (ubiquinone) Fe-S protein 1, 75\u00a0kDa (NADH-coenzyme Q reductase) [ Homo sapiens (human) ]. April 8 2014 [cited 2014 April 9]; Available from: http:\/\/www.ncbi.nlm.nih.gov.ezproxy.lib.ryerson.ca\/gene\/4719 ."},{"key":"473_CR47","unstructured":"COX18 COX18 cytochrome C oxidase assembly factor [Homo sapiens (human)]. April 8 2014 [cited 2014 April 9]; Available from: http:\/\/www.ncbi.nlm.nih.gov.ezproxy.lib.ryerson.ca\/gene\/285521 ."},{"key":"473_CR48","doi-asserted-by":"crossref","unstructured":"Gon\u00e7alves, V.F., et al., A Hypothesis-Driven Association Study of 28 Nuclear-Encoded Mitochondrial Genes with Antipsychotic-Induced Weight Gain in Schizophrenia. Neuropsychopharmacology, 2013.","DOI":"10.1038\/npp.2013.312"},{"issue":"1","key":"473_CR49","doi-asserted-by":"crossref","first-page":"e004158","DOI":"10.1136\/bmjopen-2013-004158","volume":"4","author":"PL Ishoy","year":"2014","unstructured":"Ishoy PL et al. Treatment of antipsychotic-associated obesity with a GLP-1 receptor agonist\u2013protocol for an investigator-initiated prospective, randomised, placebo-controlled, double-blinded intervention study: the TAO study protocol. BMJ Open. 2014;4(1):e004158.","journal-title":"BMJ Open"},{"issue":"4","key":"473_CR50","doi-asserted-by":"crossref","first-page":"423","DOI":"10.2217\/pgs.13.247","volume":"15","author":"EJ Brandl","year":"2014","unstructured":"Brandl EJ et al. Genetic variation in the GCG and in the GLP1R genes and antipsychotic-induced weight gain. Pharmacogenomics. 2014;15(4):423\u201331. One of the first studies implicating genes from glucose metabolism, particularly GLP1 and GCG.","journal-title":"Pharmacogenomics"},{"issue":"4","key":"473_CR51","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1038\/sj.mp.4000750","volume":"5","author":"A Petronis","year":"2000","unstructured":"Petronis A et al. Psychiatric epigenetics: a new focus for the new century. Mol Psychiatry. 2000;5(4):342\u20136.","journal-title":"Mol Psychiatry"},{"issue":"6004","key":"473_CR52","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1126\/science.330.6004.611","volume":"330","author":"G Riddihough","year":"2010","unstructured":"Riddihough G, Zahn LM. Epigenetics. What is epigenetics? Introduction. Science. 2010;330(6004):611.","journal-title":"Science"},{"issue":"6","key":"473_CR53","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1093\/schbul\/sbp104","volume":"35","author":"BP Rutten","year":"2009","unstructured":"Rutten BP, Mill J. Epigenetic mediation of environmental influences in major psychotic disorders. Schizophr Bull. 2009;35(6):1045\u201356.","journal-title":"Schizophr Bull"},{"issue":"6","key":"473_CR54","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1038\/sj.mp.4001948","volume":"12","author":"J Minet-Ringuet","year":"2007","unstructured":"Minet-Ringuet J et al. Alterations of lipid metabolism and gene expression in rat adipocytes during chronic olanzapine treatment. Mol Psychiatry. 2007;12(6):562\u201371.","journal-title":"Mol Psychiatry"},{"issue":"1","key":"473_CR55","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1868-7083-6-1","volume":"6","author":"MG Melka","year":"2014","unstructured":"Melka MG et al. The effects of olanzapine on genome-wide DNA methylation in the hippocampus and cerebellum. Clin Epigenetics. 2014;6(1):1.","journal-title":"Clin Epigenetics"},{"issue":"Pt 8","key":"473_CR56","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1242\/jcs.00963","volume":"117","author":"JS Rawlings","year":"2004","unstructured":"Rawlings JS, Rosler KM, Harrison DA. The JAK\/STAT signaling pathway. J Cell Sci. 2004;117(Pt 8):1281\u20133.","journal-title":"J Cell Sci"},{"issue":"2","key":"473_CR57","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.cyto.2012.11.002","volume":"61","author":"M Pijet","year":"2013","unstructured":"Pijet M et al. Leptin impairs myogenesis in C2C12 cells through JAK\/STAT and MEK signaling pathways. Cytokine. 2013;61(2):445\u201354.","journal-title":"Cytokine"},{"issue":"3","key":"473_CR58","doi-asserted-by":"crossref","first-page":"261","DOI":"10.2217\/epi.12.25","volume":"4","author":"KJ Burghardt","year":"2012","unstructured":"Burghardt KJ et al. DNA methylation in schizophrenia subjects: gender and MTHFR 677C\/T genotype differences. Epigenomics. 2012;4(3):261\u20138.","journal-title":"Epigenomics"},{"issue":"3","key":"473_CR59","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1038\/tpj.2012.6","volume":"13","author":"SA Lott","year":"2013","unstructured":"Lott SA et al. The influence of metabolic syndrome, physical activity and genotype on catechol-O-methyl transferase promoter-region methylation in schizophrenia. Pharmacogenomics J. 2013;13(3):264\u201371.","journal-title":"Pharmacogenomics J"},{"issue":"1","key":"473_CR60","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s40291-013-0017-8","volume":"17","author":"KJ Burghardt","year":"2013","unstructured":"Burghardt KJ, Ellingrod VL. Detection of metabolic syndrome in schizophrenia and implications for antipsychotic therapy : is there a role for folate? Mol Diagn Ther. 2013;17(1):21\u201330. Comprehensive review on epigenetic mechanisms potentially involved in AIWG, implicating modifications of the COMT and MTHFR genes, as well as discussing the role of supplementary folate.","journal-title":"Mol Diagn Ther"},{"key":"473_CR61","doi-asserted-by":"crossref","unstructured":"Schwarz, E., et al., Investigation of molecular serum profiles associated with predisposition to antipsychotic-induced weight gain. World J Biol Psychiatry, 2013. Sep 3. [Epub ahead of print]. One of the first studies implicating specific molecular serum profiles as method for predicting AIWG.","DOI":"10.3109\/15622975.2013.817685"},{"issue":"7","key":"473_CR62","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1038\/oby.2001.54","volume":"9","author":"B Vozarova","year":"2001","unstructured":"Vozarova B et al. Circulating interleukin-6 in relation to adiposity, insulin action, and insulin secretion. Obes Res. 2001;9(7):414\u20137.","journal-title":"Obes Res"},{"issue":"5708","key":"473_CR63","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1126\/science.1104342","volume":"307","author":"MA Lazar","year":"2005","unstructured":"Lazar MA. How obesity causes diabetes: not a tall tale. Science. 2005;307(5708):373\u20135.","journal-title":"Science"},{"issue":"4","key":"473_CR64","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1038\/clpt.2010.1","volume":"87","author":"MA Febbraio","year":"2010","unstructured":"Febbraio MA, Rose-John S, Pedersen BK. Is interleukin-6 receptor blockade the Holy Grail for inflammatory diseases? Clin Pharmacol Ther. 2010;87(4):396\u20138.","journal-title":"Clin Pharmacol Ther"},{"issue":"6937","key":"473_CR65","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/S0140-6736(56)92080-3","volume":"271","author":"DN Baron","year":"1956","unstructured":"Baron DN. Hypothyroidism; its aetiology and relation to hypometabolism, hypercholesterolaemia, and increase in body-weight. Lancet. 1956;271(6937):277\u201381.","journal-title":"Lancet"},{"issue":"9","key":"473_CR66","doi-asserted-by":"crossref","first-page":"13","DOI":"10.3928\/02793695-20130805-01","volume":"51","author":"RH Howland","year":"2013","unstructured":"Howland RH. A \"glucose eater\" drug as a therapeutic agent in psychiatry. J Psychosoc Nurs Ment Health Serv. 2013;51(9):13\u20136.","journal-title":"J Psychosoc Nurs Ment Health Serv"},{"issue":"6","key":"473_CR67","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.jcjd.2013.11.007","volume":"37","author":"R Ganguli","year":"2013","unstructured":"Ganguli R et al. Weight loss intervention for individuals with diabetes and serious mental illness: a pragmatic experiment in community settings. Can J Diabetes. 2013;37(6):434.","journal-title":"Can J Diabetes"}],"container-title":["Current Psychiatry Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11920-014-0473-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11920-014-0473-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11920-014-0473-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,15]],"date-time":"2022-04-15T00:40:10Z","timestamp":1649983210000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11920-014-0473-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,8,20]]},"references-count":67,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2014,10]]}},"alternative-id":["473"],"URL":"https:\/\/doi.org\/10.1007\/s11920-014-0473-9","relation":{},"ISSN":["1523-3812","1535-1645"],"issn-type":[{"value":"1523-3812","type":"print"},{"value":"1535-1645","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,8,20]]},"article-number":"473"}}